| POS-1 promotes endo-mesoderm development by inhibiting the cytoplasmic polyadenylation of neg-1 mRNA A Elewa, M Shirayama, E Kaymak, PF Harrison, DR Powell, Z Du, ... Developmental cell 34 (1), 108-118, 2015 | 23 | 2015 |
| Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL–Induced B-Cell Acute Lymphoblastic Leukemia L Yang, Q Qiu, M Tang, F Wang, Y Yi, D Yi, Z Yang, Z Zhu, S Zheng, ... Clinical Cancer Research 25 (24), 7527-7539, 2019 | 16 | 2019 |
| Treating multiple myeloma in the context of the bone marrow microenvironment M Ho, A Xiao, D Yi, S Zanwar, G Bianchi Current Oncology 29 (11), 8975-9005, 2022 | 13 | 2022 |
| Next-generation chimeric antigen receptor T cells D Yi, M Gergis, J Hsu, Y Yang, X Bi, M Aljurf, U Gergis Hematology/Oncology and Stem Cell Therapy 15 (3), 11, 2022 | 6 | 2022 |
| Dasatinib and interferon alpha synergistically induce pyroptosis-like cell death in philadelphia chromosome positive acute lymphoblastic leukemia Y Dai, J Huang, P Kuang, Y Hu, Q Zeng, W Zhang, H Li, F Wang, T Guo, ... American Journal of Cancer Research 12 (6), 2817, 2022 | 4 | 2022 |
| Allogeneic chimeric antigen receptor T cells for hematologic malignancies Y Yang, X Bi, M Gergis, D Yi, J Hsu, U Gergis Hematology/Oncology and Stem Cell Therapy 15 (3), 10, 2022 | 4 | 2022 |
| Targeting glutaminase1 and synergizing with clinical drugs achieved more promising antitumor activity on multiple myeloma Q Qiu, M Li, L Yang, M Tang, L Zheng, F Wang, H Qiu, C Liang, N Li, D Yi, ... Oncotarget 10 (57), 5993, 2019 | 4 | 2019 |
| Chimeric antigen receptor T-cell therapy for acute myeloid leukemia X Bi, J Hsu, M Gergis, Y Yang, D Yi, U Gergis Hematology/Oncology and Stem Cell Therapy 15 (3), 131-136, 2022 | 3 | 2022 |
| Chimeric antigen receptor T-cell therapies in lymphoma patients with central nervous system involvement D Yi, M Gergis, G Elgohary, J Hsu, Y Yang, X Bi, U Gergis Hematology/Oncology and Stem Cell Therapy 15 (3), 7, 2022 | 2 | 2022 |
| Chimeric antigen receptor T cell therapy for solid tumors J Hsu, Y Yang, M Gergis, X Bi, D Yi, U Gergis Hematology/Oncology and Stem Cell Therapy 15 (3), 9, 2022 | 1 | 2022 |
| Screening ABL1 kinase domain mutations in patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) H Li, W Zhang, D Yi, Y Ye, X Xiao Leukemia & Lymphoma 58 (4), 1005-1007, 2017 | 1 | 2017 |
| Clinical features, molecular findings, and clinical outcomes of follicular dendritic cell sarcoma. D Yi, K Rech, S Lester, W Breen, S Zanwar, G Ruan, SI Robinson, ... Journal of Clinical Oncology 42 (16_suppl), e23554-e23554, 2024 | | 2024 |
| Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Patients with Central Nervous System Involvement, a Systematic Review and Meta-analysis G Elgohary, Y Yang, M Gergis, D Yi, U Gergis Clinical Lymphoma Myeloma and Leukemia, 2024 | | 2024 |
